Latest Content

Explore how transcranial magnetic stimulation enhances athletic performance and mental health, offering innovative solutions for athletes facing psychological challenges.

"But when I finally learned to feel everything, I became a psychiatrist who touches nothing but a patient’s hand at the first meeting and the final good bye..."

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Psychiatric Times celebrates 40 years of impactful insights, exploring key topics in psychiatry, including medication management and emerging treatments.

Explore the challenges of protecting privacy in AI chatbots and discover expert insights on navigating data security in a profit-driven landscape.

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

Dr. Carrie Soloway's legacy inspires courage in transgender individuals, highlighting the ongoing challenges and triumphs in mental health and identity.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.

Explore innovative solutions to combat burnout in health care, including coaching, psychedelics, and addressing administrative harm for lasting change.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

American psychiatry struggles with understanding psychopathology, emphasizing the need to return to its roots for accurate diagnosis and effective treatment.

What were the top psychiatric hits of 2025?